Cargando…
Cost-effectiveness of grass pollen SCIT compared with SLIT and symptomatic treatment
BACKGROUND: Whereas specific immunotherapy (SIT) has already been shown to be cost-effective in the treatment of allergic rhinitis compared with symptomatic treatment, only a small number of investigations have compared sublingual (SLIT) and subcutaneous (SCIT) immunotherapeutic approaches. This ana...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Medizin
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5288417/ https://www.ncbi.nlm.nih.gov/pubmed/28217432 http://dx.doi.org/10.1007/s40629-016-0002-y |
_version_ | 1782504323487367168 |
---|---|
author | Reinhold, Thomas Brüggenjürgen, Bernd |
author_facet | Reinhold, Thomas Brüggenjürgen, Bernd |
author_sort | Reinhold, Thomas |
collection | PubMed |
description | BACKGROUND: Whereas specific immunotherapy (SIT) has already been shown to be cost-effective in the treatment of allergic rhinitis compared with symptomatic treatment, only a small number of investigations have compared sublingual (SLIT) and subcutaneous (SCIT) immunotherapeutic approaches. This analysis discusses the cost-effectiveness of SCIT compared with SLIT and a symptomatic treatment modality. At the same time, particular attention is paid to preparation-specific characteristics. METHODS: The investigation is based on a previously published health economic model calculation. A Markov model, with predefined disease stages and a time period of 9 years, formed the basis of the analysis. The data on specific SCIT (Allergovit®) and SLIT (Oralair®) preparations required for the calculation were adjusted for the present analysis. Quality-adjusted life years (QALYs) based on symptom scores were calculated as the endpoint for effectiveness. Furthermore, the total costs and cost effectiveness of SCIT were determined. Model uncertainties were estimated by means of additional sensitivity analyses. RESULTS: With regard to effectiveness, both the SCIT and SLIT preparations proved superior compared to symptomatic treatment. Although more expensive, SIT seem to be cost-effective. A direct comparison of SCIT (Allergovit®) and SLIT (Oralair®) showed lower total costs for SCIT treatment over the study period (SCIT 1159 € versus SLIT 1322 €) and improved effectiveness (SCIT 7.112 QALYs versus SLIT 7.060 QALYs). DISCUSSION: SIT represents a cost-effective treatment option for patients with allergic rhinitis compared with symptomatic treatment. The comparison of SCIT (Allergovit®) and SLIT (Oralair®) showed SCIT to be predominant and cost-effective, due in particular to somewhat greater patient compliance and lower drug costs. It also became evident that, as far as possible, product-specific model variables are required for an economic evaluation of SIT treatment. |
format | Online Article Text |
id | pubmed-5288417 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Springer Medizin |
record_format | MEDLINE/PubMed |
spelling | pubmed-52884172017-02-16 Cost-effectiveness of grass pollen SCIT compared with SLIT and symptomatic treatment Reinhold, Thomas Brüggenjürgen, Bernd Allergo J Int Original Article BACKGROUND: Whereas specific immunotherapy (SIT) has already been shown to be cost-effective in the treatment of allergic rhinitis compared with symptomatic treatment, only a small number of investigations have compared sublingual (SLIT) and subcutaneous (SCIT) immunotherapeutic approaches. This analysis discusses the cost-effectiveness of SCIT compared with SLIT and a symptomatic treatment modality. At the same time, particular attention is paid to preparation-specific characteristics. METHODS: The investigation is based on a previously published health economic model calculation. A Markov model, with predefined disease stages and a time period of 9 years, formed the basis of the analysis. The data on specific SCIT (Allergovit®) and SLIT (Oralair®) preparations required for the calculation were adjusted for the present analysis. Quality-adjusted life years (QALYs) based on symptom scores were calculated as the endpoint for effectiveness. Furthermore, the total costs and cost effectiveness of SCIT were determined. Model uncertainties were estimated by means of additional sensitivity analyses. RESULTS: With regard to effectiveness, both the SCIT and SLIT preparations proved superior compared to symptomatic treatment. Although more expensive, SIT seem to be cost-effective. A direct comparison of SCIT (Allergovit®) and SLIT (Oralair®) showed lower total costs for SCIT treatment over the study period (SCIT 1159 € versus SLIT 1322 €) and improved effectiveness (SCIT 7.112 QALYs versus SLIT 7.060 QALYs). DISCUSSION: SIT represents a cost-effective treatment option for patients with allergic rhinitis compared with symptomatic treatment. The comparison of SCIT (Allergovit®) and SLIT (Oralair®) showed SCIT to be predominant and cost-effective, due in particular to somewhat greater patient compliance and lower drug costs. It also became evident that, as far as possible, product-specific model variables are required for an economic evaluation of SIT treatment. Springer Medizin 2016-11-21 2017 /pmc/articles/PMC5288417/ /pubmed/28217432 http://dx.doi.org/10.1007/s40629-016-0002-y Text en © The Author(s) 2016 |
spellingShingle | Original Article Reinhold, Thomas Brüggenjürgen, Bernd Cost-effectiveness of grass pollen SCIT compared with SLIT and symptomatic treatment |
title | Cost-effectiveness of grass pollen SCIT compared with SLIT and symptomatic treatment |
title_full | Cost-effectiveness of grass pollen SCIT compared with SLIT and symptomatic treatment |
title_fullStr | Cost-effectiveness of grass pollen SCIT compared with SLIT and symptomatic treatment |
title_full_unstemmed | Cost-effectiveness of grass pollen SCIT compared with SLIT and symptomatic treatment |
title_short | Cost-effectiveness of grass pollen SCIT compared with SLIT and symptomatic treatment |
title_sort | cost-effectiveness of grass pollen scit compared with slit and symptomatic treatment |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5288417/ https://www.ncbi.nlm.nih.gov/pubmed/28217432 http://dx.doi.org/10.1007/s40629-016-0002-y |
work_keys_str_mv | AT reinholdthomas costeffectivenessofgrasspollenscitcomparedwithslitandsymptomatictreatment AT bruggenjurgenbernd costeffectivenessofgrasspollenscitcomparedwithslitandsymptomatictreatment |